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Abstract: Skin hyperpigmentation involves a broad range of skin conditions, including epidermal pigmented lesions, 
dermal pigmented lesions, and mixed pigmented lesions. Treatment includes various modalities such as brightening 
cream, chemical peeling, and laser therapy. Responses to various treatment modalities can be quite varied depending 
on the type of treatment and the degree of pigmentation. Sometimes a lesion can lighten or even partially disappear, 
while other lesions may recur. This paper provides a brief overview of treatment modalities available for 
hyperpigmented skin lesions including the importance of photoprotection, various types of brightening creams, 
suitable types of chemical peels, specific laser therapies targeted for skin hyperpigmentation, and surgery. 
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Introduction 
The management of skin pigmentation disorders poses a 
significant challenge to both patients and doctors. A 
doctor’s goal to achieve successful elimination of 
pigmentary lesions rests on two basic principles: 1) 
minimising detrimental effects of sunlight radiation, and 
2) optimising conditions of the pigmentary disorder with 
available treatment modalities. Although currently 
available sun protection skin care products are 
increasingly varied and sophisticated, its primary 
function remains to reduce the adverse effects of sun 
radiation. 
Skin pigmentation disorders manifest as skin lesions 
arising from the melanocytic system of the skin. It can be 
classified as hyperpigmentation lesions (i.e., extrinsic 
and intrinsic factors imposed on the body that cause 
excessive pigmentation) or hypopigmentation lesions 
(i.e., underlying conditions that inhibit pigmentation 
resulting in decreased melanin production). Pigmentation 
is the result of melanin pigment production in the 
melanocytes of the epidermis. Melanin synthesis is 
stimulated by sunlight and is controlled by the pituitary 
gland via melanocyte-stimulating hormone (MSH). 
Melanin synthesis is also influenced by endocrine 
secretions, including oestrogen and androgen. The 
number of melanocytes is the same between races; 
however, the amount of melanin production varies upon 
stimulation. The melanin in the skin has protective 
effects from sunlight radiation. The rising trend is that 
epidermal pigmentation has a direct relationship with the 
degree of sun exposure. Skin pigmentation affects all 
ethnic and racial groups; however, skin pigmentation 
disorders primarily affect fair- skinned populations. The 
closer the light-skinned races are to the equator, the 
higher the incidence of skin pigmentation. However, 
increased pigmentation can be due to causes other than 
melanin. Table 1 listed the factors that contribute to 
hyperpigmentation disorders. Treatment modalities of 
epidermal melanin-induced hyperpigmentation have 
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emphasised on not only curative therapy but also 
preventive measures from sun exposure. The new trend 
of treating pigmented epidermal lesions has improved 
exponentially with the advancement of research and 
development of skin care products and lasers.  
Photosensitive pigmentation is commonly localised on 
areas of the body exposed to the sun, primarily on the 
face (forehead, cheeks, and upper lip), hands, and back. 
In darker Asian, and Mediterranean skin types, the 
appearance of solar lentigines, seborrheic keratosis, and 
melasma are particularly common. This paper will 
present a brief overview of the treatment modalities for 
acquired skin pigmentation.  
 
Table 1. Causes of skin hyperpigmentation 
Causes of increased melanin production 
Non-melanin 
causes Acquired 
Congenital/   
Inherited 
Melasma 
Post-inflammatory              
 pigmentation 
Solar lentigines 
Ephelides 
Lichen planus 
Fixed drug    
 eruption 
Erythromelanosis  
 follicularis faciei   
 et colli 
Pellagra 
Poikiloderma of  
 Civatte 
Riehl’s melanosis 
Mongolian spots 
Naevus of Ota 
Naevus of Ito 
Spindle cell naevus 
Blue naevus 
Halo naevus 
Café au lait 
Peutz-Jegher’s   
 syndrome 
Albright’s syndrome 
Primary       
 haemochromatosis 
Hepatic cirrhosis 
Chronic renal   
 failure 
Alkaptonuria 
Lamellar ichthyosis 
Epidermolytic   
 hyperkeratosis 
Drug and heavy  
 metal toxicity 
Canthaxanthin 
Pituitary tumours 
 
Photoprotection 
Sun protection is of utmost importance in the treatment 
of skin hyperpigmentation. The use of full spectrum 
sunscreens should be emphasised before, during, and 
after procedures. Only sunscreen has a confirmed benefit 
in the treatment of skin hyperpigmentation. Daily use of 
sunscreen with a sun protection factor (SPF) of at least 
15 is valuable for sun protection. Sunscreen must be 
applied to all exposed skin including the lips, scalp, and 
ears. Sunscreen should be applied 15–30 min before sun 
exposure and reapplied every 2 h. The reapplication of 
sunscreen is required after swimming or heavy sweating. 
Outdoor activity during peak tanning or burning 
hours, between 10 a.m. and 4 p.m., should be minimised 
or avoided. All patients who are active outdoors should 
wear additional sun-protective apparel to reduce sunlight 
radiation exposure. Tanning beds could aggravate skin 
hyperpigmentation.  
Brightening agents 
Topical brightening agents serve a crucial role in 
achieving the lightening of skin hyperpigmentation. These 
are composed of natural or synthetic bleaching 
components which mainly suppress melanocytic activity 
and help reduce hyperpigmentation. These agents are 
commonly used as topical products to achieve optimal 
results after prolonged application. Commonly 
used brightening agents include hydroquinone, kojic acid, 
licorice extract, arbutin, ascorbic acid, glycolic acid, 
niacinamide, azelaic acid, retinoids, and others.  
Hydroquinone 
Hydroquinone has the advantage of being well tolerated, 
easily available with prescription, and inexpensive. 
These agents are composed of extractions from plants 
such as tea and coffee, and have an inhibitory effect on 
tyrosinase which lead to the reduction of melanosomes. 
Melanocytes are present in the basal layer of the 
epidermis, producing melanosomes containing melanin 
which is synthesised from tyrosine with the action of 
tyrosinase. Hydroquinones are usually combined with 
tretinoin to achieve optimal depigmentation results. At a 
concentration of 4%–6%, hydroquinone is effective in 
treating skin hyperpigmentation, including post- 
inflammatory hyperpigmentation, melasma, freckles, age 
spots, and acne scars. However, prolonged use of 
hydroquinone (for more than three months) has been    
associated with exogenous ochronosis (per- 
sistent blue-black pigmentation) in Fitzpatrick groups V 
and VI
[1]
. 
Kojic acid 
Kojic acid is a type of bleaching agent harvested from 
Japanese fungus, namely Penicillium and Aspergillus
[2]
. 
These bleaching agents are mild inhibitors of the 
formation of pigments in plant and animal tissues, and 
are used in cosmetics to brighten skin colour. 
These bleaching agents have a mild inhibitory action on 
tyrosinase. Kojic acid at a concentration of 4% or in 
combination with alpha hydroxy acid (AHA) can cause 
skin exfoliation to accelerate the lightening result. Kojic 
acid is used to treat skin disorders such as melasma
[3]
. 
Licorice extract  
Licorice is the root of Glycyrrhiza glabra
[4]
. Most 
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licorices are used as flavouring agents for tobacco, 
candies, sweeteners, and herbal medicines. The main 
component of licorice is glabridin which has been 
reported to prevent ultraviolet light B-induced skin 
pigmentation. Clinical trials have demonstrated that 
licorice has promising tyrosinase inhibition and that it 
has an influence on both melanogenesis and skin 
inflammation
[5,6]
. Licorice is very effective in treating 
post-inflammation hyperpigmentation but it is expensive. 
Skin hyperpigmentation could be optimised with licorice 
extract at concentrations ranging from 10%–40%[7]. The 
reduction of hyperpigmentation is also accelerated when 
licorice extract is combined with kojic acid and vitamin 
E in topical applications. 
Arbutin 
Arbutin is an extract from a bearberry plant of the genus 
Arctostaphylos. It is also found in wheat and Bergenia 
crassifolia
[8]
. Arbutin has a skin-lightening effect by 
decreasing both tyrosinase activity and melanin content. 
Hence, it is used in skin-lightening treatments at 
concentrations of 3%–7% and has been reported to be 
effective in treating liver spots and freckles
[9]
. 
Hydroquinone has been banned by the European 
Committee due to the risks of side effects. Arbutin is an 
alternative and gentler form of hydroquinone. Arbutin 
has advantages with long-term usage, and it can be used 
once or twice daily. In vivo experimental studies have 
demonstrated that arbutin is a safe and 
effective brightening treatment for hyperpigmented 
lesions
[9,10]
.  
Ascorbic acid 
Ascorbic acid (vitamin C), derived from fruits and green 
leafy vegetables, is a type of water-soluble vitamin and is 
present as a potent antioxidant in human skin
[3,11]
. 
Ascorbic acid inhibits melanin synthesis by interfering 
with the action of tyrosinase. The disadvantages of 
ascorbic acid are that it is rapidly oxidised, highly 
unstable, and its hydrophilic property limits its skin 
penetration
[3,12]
. Hakozaki et al. have demonstrated an 
enhanced skin-lightening effect by increasing 
transepidermal penetration and vitamin C efficacy using 
ultrasound
[13]
.  
Glycolic acid 
Skin-lightening treatments would have more effective 
results if preceded by thorough exfoliation. Glycolic acid 
is derived from sugar cane. It is a weak organic acid, and 
is reportedly effective in treating solar lentigines, melasma, 
and post-inflammatory hyperpigmentation
[14]
. At low 
concentrations, it promotes exfoliation of pigmented 
keratinocytes and facilitates brightening cream 
penetration. However, any brightening cream treatment 
must be stopped at least three days prior to chemical 
peeling treatment to prevent complications such as 
epidermolysis. 
Niacinamide (vitamin B3) 
Niacinamide is an amide form of vitamin B3 (niacin) and 
is a water-soluble vitamin. It can be found in trace 
amounts in fish, nuts, mushrooms, and root vege-    
tables
[15,16]
. Niacinamide has various beneficial medical 
applications. It has anti-inflammatory actions and 
may be beneficial to patients with inflammatory skin 
conditions such as acne vulgaris
[17]
. Hakozaki et al. 
demonstrated in vitro that niacinamide exhibited 
effective skin-lightening activity by inhibiting the 
transfer of melanosomes to adjacent keratinocytes by 
35%–68%[18,19]. In a clinical study, Navarrete-Solís et al. 
reported that 8 weeks of treatment with 4% niacinamide 
cream showed good to excellent improvement in 44% of 
patients with melasma, compared to 55% from a 4% 
hydroquinone cream treatment
[20]
.  
Azelaic acid 
Azelaic acid is derived from wheat, rye, and barley. It 
has been used for treating melasma and post- 
inflammatory hyperpigmentation. It is an alternative to 
hydroquinone treatment for skin pigmentation. It works 
as a tyrosinase inhibitor. A clinical study conducted by 
Breathnach has shown that a topical application of 20% 
azelaic acid is superior to 2% hydroquinone in patients 
with melasma
[1,21]
. Another clinical trial conducted by 
Baliña et al. found no significant differences between 
treating melasma with 20% azelaic acid cream and 4% 
hydroquinone cream. 65% of patients treated with 
azelaic acid were reported to have achieved good to 
excellent results versus 73% of patients treated with 
hydroquinone that achieved similar results
[22]
.  
Retinoids 
Retinoids are composed of chemical compounds related 
to vitamin A. It is widely used in medicine, and 
its beneficial effects are primarily attributed to the 
regulation of epithelial cell growth. Topical applications 
of these agents are indicated for dermatological 
conditions with increased cell turnover such as 
psoriasis
[23]
 and inflammatory skin disorders such as 
acne
[24]
. Retinoids are also ideal for treating photoaging 
and skin wrinkles
[25,26]
. The inhibition of tyrosinase 
action provides an effective environment for reducing 
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hyperpigmentation. Other mechanisms of action include 
a dispersion of pigmented granules in keratinocytes, a 
reduction in pigment transfer, and an acceleration of 
epidermal exfoliation
[27]
. Retinoids are suitable as 
long-term medications and have favourable safety 
profiles. When applying topical retinoids, a 0.025% 
concentration should be utilised initially as local adverse 
effects, including erythema, pruritus, and dryness, occur 
frequently during the early treatment phase
[28]
. 
Subsequently, treatment can be increased gradually every 
week up to a daily use of the cream at a concentration of 
0.1%. Pathak et al. demonstrated that the treatment of 
melasma should include a topical formulation of cream 
containing 2% hydroquinone and 0.05% to 0.1% retinoic 
acid
[29]
. 
Other active ingredients 
Other ingredients under in vitro investigation include 
linoleic acid which is an unsaturated fatty acid, extracts 
from a type of Chilean snail, Helix aspersa, and lumixyl 
which is a synthetic oligopeptide that exhibits inhibitory 
activity against human tyrosinase. 
Chemical peels 
Chemical peeling is a popular option for facial 
rejuvenation and treatment of superficial hyper- 
pigmentation. A wide spectrum of chemical peels is 
available, producing variable effects on the skin. Fine 
and coarse facial rhytides and uneven skin pigmentations 
that are not effectively treated surgically can be treated 
with chemical peels. Chemical peeling affects the 
epidermis and superficial dermis by smoothing 
irregularities and altering skin pigmentation. Different 
solutions are used to target skin injury at specific depths, 
resulting in the removal of damaged skin with 
pigmentation. Superficial and medium-depth chemical 
peels are desirable due to their safety records, 
effectiveness, relatively low costs, and rapid recovery 
times. Major indications for chemical peel treatments are 
solar lentigines and other signs of photodamage 
including rhytides, scarring, actinic keratosis, melasma, 
and acne vulgaris. In the early phase of photodamage, 
skin which exhibits pigmentary changes without 
wrinkles will respond effectively to repetitive superficial 
peels
[30]
. Lesions arising from deeper layers of the skin, 
such as actinic keratosis and melasma, require treatment 
with one or more medium-depth peels.  
 All patients should be adequately prepared prior to 
chemical peeling. Gentle facial washing is required prior 
to a superficial chemical peel. For medium peels, 
residual oils, make-up, and debris must be removed 
thoroughly prior to applying chemical peel solutions. The 
following discussion will specifically provide an 
overview of chemical peeling solutions suitable for 
treating skin hyperpigmentation.  
Glycolic acid at 20%–70% 
Glycolic acid peels use materials derived from sugar- 
cane. Weekly or biweekly peels using 40%–70% 
unbuffered glycolic acid is a method of superficial 
peeling. Penetration depth is related to the concentration 
and duration of the treatment. A patient’s skin will 
naturally develop tolerance to glycolic acid peels. 
Therefore, a regime should start with a low-strength 
glycolic peel of 20%–30% applied for 2 min. Patient’s 
level of pain and erythema are the two main factors 
determining the endpoint of glycolic acid peels. A typical 
peel regime includes 6 peels with each peel one month 
apart. At subsequent visits, patient’s tolerance to pain and 
their recovery time can be evaluated. If the patient 
tolerated the previous glycolic acid peel well, the 
subsequent peel can be escalated to 40%–50% glycolic 
acid, or maintained at the same concentration of the 
previous glycolic acid peel (i.e., 20%–30%) and left on 
the skin longer, for approximately 5–6 min. Glycolic acid 
peels require dilution with water or neutralisation with  
5% sodium bicarbonate
[31]
. Glycolic acid is found in 
many cosmetics at low concentrations. A low 
concentration of glycolic acid may be used as a primer 
for a chemical peel or for laser resurfacing. 
Salicylic acid at 20%–30% 
Salicylic acid is a type of beta-hydroxy acid. It has an 
anti-inflammatory effect and thus helps to diminish 
inflammation-induced hyperpigmentation. Joshi et al. 
demonstrated that salicylic acid peels at 20% to 30% are 
safe and clinically effective for patients with Fitzpatrick 
skin types IV to VI and post-inflammatory 
hyperpigmentation
[32]
. Salicylic acid peels can remove 
the stratum corneum and stratum granulosum with an 
exfoliation process. This will stimulate the generation of 
new epithelium. Kligman et al. demonstrated that single 
and multiple salicylic acid peels at 30% applied at 
4-week intervals resulted in significant improvements of 
pigmentation in patients with moderately photodamaged 
skin
[33]
. 
Blue peel 
Variable results often occur with various chemical peels 
due to lack of control over the depth of the peel. 
Trichloroacetic acid (TCA)-based blue peel facilitates the 
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treatment of the papillary dermis and immediate reticular 
dermis. TCA-based blue peel is formed by mixing TCA 
at a fixed concentration (15%–20%) and volume with 
the blue peel base which contains glycerine, saponins, 
and a non-ionic blue colour base. This forms a 
homogenous TCA-oil-water solution for slow 
penetration and an even coating. An even blue colour 
demonstrates the uniformity of an application. Hence, the 
depth of the peel can be easily recognisable. Blue peel 
has no systemic side effects or toxicity
[34]
. 
 Frosting occurs as a result of protein denaturation 
and coagulation. Pink frost develops as the papillary 
dermis is reached. This will become white frosting as the 
peel acts at the immediate reticular dermis. The time 
required for the blue peel solution to begin exerting its 
action due to initial acid neutralisation by dermal protein 
is approximately 2 min. Erythema will last for 3–7 days. 
The use of topical antibiotics and acyclovir should be 
considered as bacterial and viral infections are common. 
With increasing peel depth, scarring and pigment 
change become more likely. A typical regime includes 
two or three blue peels, and the peels are typically spaced 
6–8 weeks apart for maximum effect.  
Lasers 
Lasers are based on Einstein’s theory of stimulated 
emission of radiation. In 1960, Theodore Harold Maiman 
invented and developed light amplification by stimulated 
emission of radiation (LASER) using a synthetic ruby 
crystal
[35]. Maiman’s invention led to the subsequent 
development of various types of lasers. Laser resurfacing 
removes discolourations, age spots, and photodamaged 
skin. There are specific lasers for pigmented skin lesions 
such as lasers with blue, green, red, and near-infrared 
wavelengths. Various laser systems can be applied to 
treat skin hyperpigmentation (Table 2). However, lasers 
should be applied with caution as they will result in 
paradoxical effect of hyperpigmentation following treat-
ment if no proper information was given to patients.  
Continuous wave lasers 
Continuous wave lasers supply an uninterrupted beam of 
laser light without pulses. Long exposures to these lasers 
can result in thermal damage to adjacent tissues. 
Argon lasers  
An argon laser at a wavelength of 514 nm prod-      
uces blue-green light. Continuous wave argon lasers and 
argon lasers are pulsed using a mechanical shutter target 
melanin. Therefore, argon lasers have been used in the 
past to treat port-wine stains and superficial 
pigmentation
[36]
. However, scarring and depigmentation 
are commonly observed in argon laser-treated lesions. 
These unwanted side effects are due to the strong 
absorption of argon lasers by melanin and the diffusion 
to surrounding tissues.  
 
Table 2. Various laser resurfacing systems for treating skin 
hyperpigmentation 
Laser types 
Wavelength  
(nm) 
Clinical Applications 
Continuous wave 
Argon 514 Birthmarks, port wine stains 
Flashlight-pumped 
pulsed dye (green) 
510 
Benign epidermal pigmented 
lesions 
Copper vapour 511 Lentigines 
Krypton 520 Epidermal pigmented lesions 
KTP:YAG 532 Benign pigmented lesions 
CO2 (pulsed) 10,600 
Various epidermal and dermal 
lesions 
Quality-switched (Q-switched) 
Ruby 694 
Benign pigmented lesions, dark 
tattoos 
Alexandrite 755 
Benign pigmented lesions, dark 
tattoos 
Nd:YAG 1,064 
Pigmented dermal lesions, dark 
tattoos 
Flashlight-pumped pulsed dye lasers (green) 
Flashlight-pumped pulsed dye lasers (green) (FPPDLs) 
are delivered in short single pulses or a train of pulses at 
high peak powers. These green-dyed lasers contain 
fluorescent dyes which are absorbed in water and alcohol. 
Therefore, the 510 nm wavelength is absorbed well by 
melanin, making it suitable for treating benign 
pigmented skin lesions
[36]
. It penetrates to a depth of 
0.75–1.0 mm. In Fitzpatrick V–VI skin, this treatment 
may damage melanocytes, leading to hypopigmentation. 
Copper vapour lasers 
Copper vapour lasers generate light at a wavelength of 
511 nm, similar to that of FPPDLs, but the pulses are 
much shorter at 22 ns compared with 450 μs for FPPDLs. 
These continuous wave copper vapour lasers emit pulses 
at very high frequencies (5,000–15,000 Hz). Therefore, 
these lasers present a higher risk of hypertrophic 
scarring
[37]
. Copper vapour lasers at 511 nm have been 
effective in treating lentigines.   
Krypton lasers 
Krypton lasers are a type of continuous wave lasers. 
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These lasers emit light at 520 nm (green) which is 
effective for treating pigmented epidermal lesions
[36]
. 
The common problem with krypton lasers is the heating 
of the skin surface due to strong scattering of light. 
Hence, skin cooling prior and during this procedure is of 
utmost importance.  
KTP:YAG lasers  
Potassium-titanyl-phosphate (KTP) lasers have a wav-
elength of 532 nm which targets melanin. These lasers 
are effective in treating benign skin hyperpigmentation 
such as melasma. In cases of melasma, KTP functions by 
generating gentle heat in melanosomes with long pulses 
(millisecond) rather than causing mechanical destruction 
of the target chromophores. KTP lasers greatly reduce 
redness and pigmentation compared to Nd:YAG lasers in 
patients requiring skin rejuvenation
[38]
. 
CO2  
The active laser medium is a mixture of carbon dioxide, 
nitrogen, and helium gases. This combination of gases 
generates a laser beam with a wavelength of 10,600 nm 
which is in the middle of the infrared spectrum and is 
therefore invisible. With a hand piece, the beam is aimed 
to transmit helium ion light. The target chromophore of 
the CO2 laser is water. The laser spot is focused at a 
depth of 0.1–2.0 mm in the skin, and the specific amount 
of thermal build-up determines whether the treatment 
results in ablation, cutting or coagulation at the cellular 
level. The mainstay of CO2 laser is ablative tissue 
resurfacing; therefore, it is effective for both benign 
epidermal and dermal hyperpigmentation such as 
various benign naevi
[39]
. 
Quality-switched (Q-switched) lasers 
When one of the resonating mirrors is non-reflective for 
an interval of pumping, the stored energy is emitted at 
extremely high levels of laser energy in a nanosecond. 
These lasers allow thermal relaxation time; therefore, 
these lasers carry very little collateral damage to the 
adjacent tissue and subsequent scarring is rare
[40,41]
. 
Taylor et al. demonstrated the mechanism of pigment 
removal via laser application
[42]
. The short pulses of high 
energy cause rapid thermal expansion of the pigment 
granules and result in photoacoustic fragmentation of  
the pigments. These fragments are then             
removed by redistribution, transepidermal elimination,  
and phagocytosis
[41]
. The advantages of laser treatment 
include greater precision, higher efficacy, and lesser 
scarring than other treatment modalities. However, 
suspicious pre-malignant and malignant skin lesions are 
absolute contraindications for laser treatment. Multiple 
laser treatment sessions are required at 3–4 weeks 
intervals. Typically, 5 to 6 treatments are performed to 
achieve noticeable results. Minimal erythema and 
oedema are commonly noted immediately after laser 
treatment, and tend to resolve several hours thereafter.  
Q-switched ruby lasers 
The ruby laser was the first laser developed. It was 
initially a continuous wave and was then developed to be 
Q-switched. Q-switched ruby lasers emit light at a wave-
length of 694 nm which is useful for treating epidermal 
and dermal pigmented lesions
[43]
. 
Q-switched alexandrite 
Alexandrite laser uses a Q-switching system and emits 
light at a wavelength of 755 nm which is effective in 
treating benign pigmented lesions such as freckles
[44]
. 
Nd:YAG lasers 
The neodymium: yttrium aluminium garnet (Nd:YAG) 
laser emits light in the near-infrared band at a 
wavelength of 1,064 nm. Q-switched Nd:YAG lasers 
function by a mechanism similar to that of Q-switched 
ruby lasers. However, it was developed to avoid melanin 
absorption and further reduce the resulting 
hypopigmentation that is common with Q-switched ruby 
laser treatments. It has multiple clinical applications 
including treating pigmented lesions and tattoos
[45-49]
.  
Frequency-doubled Nd:YAG lasers 
When fitted with a K-diphosphate crystal which doubles 
the frequency and halves the wavelength to 532 nm, 
Q-switched Nd:YAG lasers are effective in treating 
epidermal hyperpigmented lesions
[43]
 and red, orange, 
and yellow tattoos. It is uncommon to have 
complications with repeated treatments.   
Skin preconditioning is an essential part of laser ther- 
apy for skin hyperpigmentation. Applications of retinoic 
acid (vitamin A) with glycolic acid preconditioning 
regimes are often used before laser resurfacing or che-
mical peels. These agents increase skin metabolism, 
accelerate cellular division, boost collagen synthesis, and 
reduce the thickness of stratum corneum. In doing so, 
subsequent therapies are more effective. Tretinoin 0.005% 
(Renova) is a topical agent that is effective for treating 
photodamaged skin and mottled pigmentation
[50]
. 
Pretreatment with retinoids may help to reduce post- 
treatment hyperpigmentation but it may contribute to 
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postoperative erythema. It is also contraindicated during 
early pregnancy due to its teratogenic effect. Renova is 
an excellent treatment for solar-induced lentigines on the 
dorsum of the hands. Overall, laser therapy for skin 
hyperpigmentation is an expensive consumable. 
Surgery 
Surgery is indicated for dermatologic lesions such as 
large congenital naevus, dysplastic naevi syndrome, mel-
anoma, pre-malignant skin lesions, and malignant skin 
lesions. 
Discussion 
With rapid development of cosmetic products, skin pr-
ocedures, and medical devices, the desire to 
have beautiful skin is achievable. Skin rejuvenation 
can be achieved by improving external appearances 
without complications. However, there are several 
important factors that should be taken into consideration 
in patient evaluation of hyperpigmentation disorders. 
These include specific skin type, skin complexion based 
on the Fitzpatrick scale, skin texture, skin thickness, 
degree of photoaging, severity of facial rhytides, aesthetic 
outcome, relative cost of treatment, patient expectation, 
and time consumption.  
The purpose of treating hyperpigmentation lesions is 
to control local factors that result in excessive melanin 
production. The ideal treatment for hyperpigmentation 
lesion would achieve this goal by applying the following 
effects: 
1. Eliminate melanin-induced hyperpigmentation; 
2. Protect skin against further injury from sun ra- 
diation and post-inflammation hyperpigmentation; 
3. Reduce oedema and erythema; 
4. Promote integrity of the surrounding tissue. 
 
There are numerous medical-grade brightening agents 
and sun protection agents available. In addition, there are 
different types of laser therapies available to treat 
hyperpigmentation disorders. The purpose of treating 
hyperpigmentation is to develop an optimal treatment 
that eliminates pigmentary lesions. Non-surgical methods 
are the most desirable methods. Among non-surgical 
methods, non-invasive treatments are the most sought 
after. In contrast with invasive treatments, no downtime 
is required after non-invasive procedures. Generally, 
hyperpigmented lesion treatments can be categorised into 
five groups: 1) photoprotection, 2) topical brightening 
agents, 3) chemical peeling, 4) laser therapy, and 5) 
surgery.  
Conclusion 
Skin hyperpigmentation is a very common skin disorder 
in all Fitzpatrick skin types. Various treatment modalities 
have been studied and have shown improvements in 
reducing pigmentation. However, no single treatment is 
effective for all types of dermal hyperpigmentation. 
A brief overview of the treatment modalities for 
hyperpigmentation has been provided. Patients with 
long-standing hyperpigmentation will need to undergo 
continued treatment depending on the duration of 
treatment, cost, patients’ compliance, and clinicians’ 
experience. Laser treatments and chemical peels remain 
popular for the treatment of skin hyperpigmentation. 
These treatments can achieve good synergistic results in 
combination with brightening creams. Lastly, clinicians 
should educate patients about the importance of 
photoprotection to optimise treatment. 
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